M Pharmaceutical Inc.
CNSX : MQ

M Pharmaceutical Inc.

February 06, 2015 12:20 ET

M Pharmaceutical Inc. (Formerly First Sahara Energy Inc.) Closes Over-Subscribed Private Placement

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 6, 2015) - M Pharmaceutical Inc., formerly First Sahara Energy Inc. ( the "Company") (CSE:MQ) announces that it has closed its previously announced private placement on an over-subscribed basis. The Company has issued 43,750,000 units at $0.02 per unit for gross proceeds of $875,000. Each unit consists of one common share in the capital of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant") entitling the holder to purchase one additional Common Share for $0.05 for a period of 12 months from closing of the Financing. Proceeds will be used for working capital, including expenses for the acquisition of the rights to the eMosquito, and certain testing and development costs thereof. Securities issued hereunder will be subject to trading restrictions until June 7, 2015.

The Company has signed an arms-length agreement to acquire and commercialize the rights to a biomedical device for the self-monitoring of blood glucose, primarily by diabetics. This device, called the eMosquito, is based on a novel in-plane actuator designed to provide minimally-invasive skin penetration to be used by persons with diabetes. The objective of the eMosquito is to obtain whole blood samples by penetrating the skin to shallower depths and in less sensitive areas of the body. Persons with diabetes have traditionally used the "finger prick" method to monitor/test their blood glucose levels. The blood sample was obtained by pricking the finger tip, a highly sensitive area of the body. The eMosquito is envisioned to be worn like a patch with small needles designed to puncture the skin just deep enough to draw blood without affecting the nerve endings and causing little or no pain. The commercial development of the eMosquito will require the successful coordination and execution of a wide variety of technology disciplines.

FORWARD LOOKING STATEMENTS

This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the acquisition and commercialization of the rights to the eMosquito. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and such factors as the Company failing to close the planned acquisition, or the failure to complete the commercialization of the eMosquito.

Contact Information